Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion

This case report corroborates the indication for patients affected by these rare tumors to be treated in higher- volume cancer centers to provide patients with more ex- perience and access to NGS diagnostic resources. Most importantly, it raises enthusiasm and hope toward precision medicine and tailored treatments for patients with PACC